Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Delanoy

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
The Lancet. Haematology|December 12, 2018
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational studyNicolas Delanoy, Jean-Marie Michot, Thibault Comont, et al.
BMJ Open|September 4, 2025
Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE studyJerome Alexandre, Philippe Boudier, Elise Lavit, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2019
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international databaseNicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2020
Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163]Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2020
Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153-163]Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Urology Oncology|June 4, 2019
Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS DatabaseNicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
The Lancet. Haematology|December 12, 2018
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational studyNicolas Delanoy, Jean-Marie Michot, Thibault Comont, et al.
BMJ Open|September 4, 2025
Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE studyJerome Alexandre, Philippe Boudier, Elise Lavit, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2019
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international databaseNicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2020
Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163]Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2020
Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153-163]Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Urology Oncology|June 4, 2019
Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS DatabaseNicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
Pageof 4